S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

K-Laser Debuts GIRO Platform to Scale Rehabilitation Therapy

With over two decades of therapeutic laser innovation behind it, K-Laser is rolling out the GIRO Rehabilitation & Sports Series across the U.S. The new platform aims to modernize clinical workflows by pairing high-power delivery with an intuitive interface, targeting the specific demands of sports medicine and physical therapy practices.

K-Laser Debuts GIRO Platform to Scale Rehabilitation Therapy
Photo: Bio & News

The GIRO series arrives as a redesigned evolution of K-Laser’s existing Class IV technology. By consolidating performance and consistency, the company intends to help clinics manage higher patient volumes without sacrificing treatment efficacy. The hardware is structured into three tiers: the Core model for growing practices, the Elite version for workflow optimization, and the Ultra for high-demand clinical environments.

Marina Rodríguez Alonso, Head of Product & Brand Management at K-Laser, noted that the platform was engineered to address the modern clinician’s need for reliable, accessible technology. Beyond the hardware, the system utilizes K-Laser’s signature multi-wavelength approach to facilitate muscle relaxation, increased local circulation, and temporary pain relief. As a subsidiary of the INDIBA Group, K-Laser positions this launch as a strategic effort to balance clinical performance with the operational efficiency required by today’s healthcare providers.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!